Anshul Maheshwari Sells 5,747 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) insider Anshul Maheshwari sold 5,747 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $19.55, for a total value of $112,353.85. Following the completion of the transaction, the insider directly owned 246,148 shares in the company, valued at approximately $4,812,193.40. This trade represents a 2.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Anshul Maheshwari also recently made the following trade(s):

• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $224,784.56.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $18.65, for a total transaction of $87,002.25.
• On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The shares were sold at an average price of $16.77, for a total transaction of $55,626.09.

SiBone Trading Up 2.5%

NASDAQ SIBN opened at $19.96 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. The stock has a market capitalization of $885.23 million, a P/E ratio of -58.71 and a beta of 0.66. The firm’s 50-day moving average is $17.49 and its two-hundred day moving average is $15.33. SiBone has a 12 month low of $11.48 and a 12 month high of $21.89.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million during the quarter, compared to analysts’ expectations of $55.34 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. On average, sell-side analysts anticipate that SiBone will post -0.4 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. UBS Group raised their price objective on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Truist Financial reaffirmed a “buy” rating and set a $23.00 target price (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. Finally, TD Cowen increased their target price on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $24.17.

Institutional Investors Weigh In On SiBone

Several large investors have recently bought and sold shares of the stock. Versant Capital Management Inc boosted its stake in shares of SiBone by 102.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after buying an additional 887 shares during the period. Bank of America Corp DE grew its position in shares of SiBone by 8.7% during the first quarter. Bank of America Corp DE now owns 419,473 shares of the company’s stock worth $5,298,000 after buying an additional 33,688 shares in the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of SiBone during the first quarter worth approximately $159,000. Quantinno Capital Management LP increased its stake in shares of SiBone by 58.2% during the first quarter. Quantinno Capital Management LP now owns 29,475 shares of the company’s stock worth $372,000 after buying an additional 10,848 shares during the period. Finally, First Light Asset Management LLC raised its holdings in SiBone by 6.4% in the first quarter. First Light Asset Management LLC now owns 5,353,190 shares of the company’s stock valued at $67,611,000 after acquiring an additional 320,286 shares in the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.